Clinical trial
A Phase I/IIa Study to Investigate the Safety, Tolerability, and Preliminary Effectiveness of HeXell-2020 in Patients With Stable Coronary Artery Disease (CAD)
NCT07137104 is registered in ClinicalTrials.gov with Hexun Biosciences Co., LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IIa Study to Investigate the Safety, Tolerability, and Preliminary Effectiveness of HeXell-2020 in Patients With Stable Coronary Artery Disease (CAD)
- Lead sponsor
- Hexun Biosciences Co., LTD.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 27, 2026
- Completion date
- July 31, 2029
- Enrollment
- 39 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.